Opening Session Panel Discussion

First International Summit on Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Deborah Collyar: What's In It for Patients?

Mar

Today In Oncology

Opening Session Panel Discussion

Related Videos

David A. Hyman, MD, JD, on Inclusive Shared Savings

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Deborah Collyar: What's In It for Patients?

Radiotherapy May Reduce Risk of Lymphedema in Patients With Breast Cancer More Effectively Than Surgery

Breast Cancer Recurrence Remains Low Even After 10 Years With Radiotherapy Tailored to Patient’s Individual Risk

Breast Reconstruction Using Polyurethane-Coated Implants May Reduce the Risk of Capsular Contracture, Additional Surgery

AI As Collaborator in Cancer Research and in Clinical Care

Metabolic Subtypes of Nasopharyngeal Carcinoma and Response to Treatment